A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification
Public ClinicalTrials.gov record NCT02906917. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
This Trial is Conducted Globally. The Aim of This Trial is to Compare the Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Trial comparing effect and safety of insulin degludec/insulin aspart vs. insulin glargine plus insulin aspart in subjects with type 2 diabetes treated with basal insulin with or without oral antidiabetic treatment in need of treatment intensification.
Study identification
- NCT ID
- NCT02906917
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 532 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 20, 2016 (Actual)
- Primary completion
- Aug 31, 2017 (Actual)
- Completion
- Dec 24, 2017 (Actual)
- Last update posted
- Nov 13, 2019
2016 – 2017
United States locations
- U.S. sites
- 30
- U.S. states
- 13
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | Glendale | Arizona | 85306-4652 | — |
| Novo Nordisk Investigational Site | Phoenix | Arizona | 85050 | — |
| Novo Nordisk Investigational Site | Anaheim | California | 92801 | — |
| Novo Nordisk Investigational Site | Concord | California | 94520 | — |
| Novo Nordisk Investigational Site | Fresno | California | 93720 | — |
| Novo Nordisk Investigational Site | La Jolla | California | 92037 | — |
| Novo Nordisk Investigational Site | Northridge | California | 91325 | — |
| Novo Nordisk Investigational Site | Danbury | Connecticut | 06810 | — |
| Novo Nordisk Investigational Site | Fort Lauderdale | Florida | 33312 | — |
| Novo Nordisk Investigational Site | Fort Lauderdale | Florida | 33316 | — |
| Novo Nordisk Investigational Site | Jacksonville | Florida | 32205 | — |
| Novo Nordisk Investigational Site | Kissimmee | Florida | 34744 | — |
| Novo Nordisk Investigational Site | Roswell | Georgia | 30076 | — |
| Novo Nordisk Investigational Site | Louisville | Kentucky | 40213 | — |
| Novo Nordisk Investigational Site | Chesterfield | Missouri | 63017 | — |
| Novo Nordisk Investigational Site | New York | New York | 10029 | — |
| Novo Nordisk Investigational Site | Westfield | New York | 14787 | — |
| Novo Nordisk Investigational Site | Wilmington | North Carolina | 28401 | — |
| Novo Nordisk Investigational Site | Franklin | Ohio | 45005 | — |
| Novo Nordisk Investigational Site | Bartlett | Tennessee | 38133 | — |
| Novo Nordisk Investigational Site | Chattanooga | Tennessee | 37411 | — |
| Novo Nordisk Investigational Site | Kingsport | Tennessee | 37660 | — |
| Novo Nordisk Investigational Site | Knoxville | Tennessee | 37938 | — |
| Novo Nordisk Investigational Site | Nashville | Tennessee | 37228 | — |
| Novo Nordisk Investigational Site | Austin | Texas | 78758 | — |
| Novo Nordisk Investigational Site | Dallas | Texas | 75390-9302 | — |
| Novo Nordisk Investigational Site | San Antonio | Texas | 78230 | — |
| Novo Nordisk Investigational Site | Chesapeake | Virginia | 23321 | — |
| Novo Nordisk Investigational Site | Midlothian | Virginia | 23114 | — |
| Novo Nordisk Investigational Site | Winchester | Virginia | 22601-3834 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02906917, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 13, 2019 · Synced Nov 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02906917 live on ClinicalTrials.gov.